J. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto et al., International Study of the Prevalence and Outcomes of Infection in Intensive Care Units, JAMA. 2 déc, vol.302, issue.21, pp.2323-2332, 2009.

, Surveillance des infections nosocomiales en réanimation adulte / 2017 / Maladies infectieuses / Rapports et synthèses / Publications et outils / Accueil

. Disponible, Surviving Sepsis Campaign: International Guidelines for Man, Critical Care

. Disponible,

I. Steffens, 20 years of communicating facts and figures, Eurosurveillance. 1 déc, vol.21, issue.48, p.30415, 2016.

J. Pitout, Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices, Drugs. 12 févr, vol.70, issue.3, pp.313-346, 2010.

J. J. Rahal, Antimicrobial resistance among and therapeutic options against gramnegative pathogens, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 août, vol.49, issue.1, pp.4-10, 2009.

W. A. Craig, Choosing an antibiotic on the basis of pharmacodynamics, Ear Nose Throat J. juin, vol.77, issue.6, pp.11-12, 1998.

J. W. Mouton and A. A. Vinks, Continuous infusion of beta-lactams. Curr Opin Crit Care, vol.13, pp.598-606, 2007.

R. Garraffo and T. Lavrut, Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation, Réanimation. juin, vol.14, issue.4, pp.264-75, 2005.

M. Ulldemolins, J. A. Roberts, J. Rello, D. L. Paterson, and J. Lipman, The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients, Clin Pharmacokinet. févr, vol.50, issue.2, pp.99-110, 2011.

B. Georges, J. Conil, T. Seguin, S. Ruiz, V. Minville et al., Population Pharmacokinetics of Ceftazidime in Intensive Care Unit Patients: Influence of Glomerular Filtration Rate, Mechanical Ventilation, and Reason for Admission, Antimicrob Agents Chemother, vol.53, issue.10, pp.4483-4492, 2009.

T. Bergan, Pharmacokinetics of beta-lactam antibiotics, Scand J Infect Dis Suppl, vol.42, pp.83-98, 1984.

J. A. Roberts and J. Lipman, Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of ?-lactams, Crit Care Lond Engl, vol.37, issue.3, p.206, 2009.

B. Claus, E. A. Hoste, K. Colpaert, H. Robays, J. Decruyenaere et al., Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy, J Crit Care, vol.28, issue.5, pp.695-700, 2013.

A. Hobbs, K. M. Shea, K. M. Roberts, and M. J. Daley, Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics. Pharmacotherapy, vol.35, pp.1063-75, 2015.

A. A. Udy, J. M. Varghese, M. Altukroni, S. Briscoe, B. C. Mcwhinney et al., Subtherapeutic initial ?-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations, Chest. juill, vol.142, issue.1, pp.30-39, 2012.

J. A. Roberts, S. K. Paul, M. Akova, M. Bassetti, D. Waele et al., DALI: defining antibiotic levels in intensive care unit patients: are current ?-lactam antibiotic doses sufficient for critically ill patients?, Clin Infect Dis Off Publ Infect Dis Soc Am. avr, vol.58, issue.8, pp.1072-83, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01954093

M. H. Abdul-aziz, J. M. Dulhunty, R. Bellomo, J. Lipman, and J. A. Roberts, Continuous betalactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care, 16 août, vol.2, p.37, 2012.

M. H. Abdul-aziz, H. Sulaiman, M. Mat-nor, V. Rai, K. K. Wong et al., BetaLactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis, Intensive Care Med, vol.42, issue.10, pp.1535-1580, 2016.

J. M. Dulhunty, J. A. Roberts, J. S. Davis, S. Webb, R. Bellomo et al., Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial, Clin Infect Dis Off Publ Infect Dis Soc Am. janv, vol.56, issue.2, pp.236-280, 2013.

P. D. Tamma, N. Putcha, Y. D. Suh, K. J. Van-arendonk, and M. L. Rinke, Does prolonged ?lactam infusions improve clinical outcomes compared to intermittent infusions? A metaanalysis and systematic review of randomized, controlled trials, BMC Infect Dis. 22 juin, vol.11, p.181, 2011.

J. J. De-waele, J. Lipman, M. Akova, M. Bassetti, G. Dimopoulos et al., Risk factors for target non-attainment during empirical treatment with ?-lactam antibiotics in critically ill patients, Intensive Care Med. sept, vol.40, issue.9, pp.1340-51, 2014.

J. A. Roberts, C. Kirkpatrick, M. S. Roberts, T. A. Robertson, A. J. Dalley et al., Méropenème dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution, J Antimicrob Chemother. juill, vol.64, issue.1, pp.142-50, 2009.

G. Dufour and P. Montravers, Pharmacokinetics of antibiotics or antifungal drugs in intensive care units, Curr Infect Dis Rep. 1 janv, vol.11, issue.1, p.14, 2009.

J. A. Roberts and J. Lipman, Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis, Clin Pharmacokinet, vol.45, issue.8, pp.755-73, 2006.

S. Bhattacharyya, R. R. Darby, P. Raibagkar, L. Castro, and A. L. Berkowitz, Antibioticassociated encephalopathy, Neurology. 8 mars, vol.86, issue.10, pp.963-71, 2016.

S. Keskin and R. J. Konkol, Seizure Exacerbation Related to Betalactam Antibiotics in a Child with Cerebral Dysgenesis, Dev Med Child Neurol. 1 mars, vol.35, issue.3, pp.267-74, 1993.

R. Sutter, S. Rüegg, and S. Tschudin-sutter, Seizures as adverse events of antibiotic drugs: A systematic review, Neurology, vol.85, issue.15, pp.1332-1373, 2015.

J. Sonck, G. Laureys, and D. Verbeelen, The neurotoxicity and safety of treatment with cefepime in patients with renal failure, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc-Eur Ren Assoc. mars, vol.23, issue.3, pp.966-70, 2008.

G. Wong, A. Brinkman, R. J. Benefield, M. Carlier, D. Waele et al., An international, multicentre survey of ?-lactam antibiotic therapeutic drug monitoring practice in intensive care units, J Antimicrob Chemother. mai, vol.69, issue.5, pp.1416-1439, 2014.

F. B. Sime, M. S. Roberts, S. L. Peake, J. Lipman, and J. A. Roberts, Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care, 28 juill, vol.2, p.35, 2012.

P. Longuet, A. L. Lecapitaine, B. Cassard, R. Batista, R. Gauzit et al., Preparing and administering injectable antibiotics: How to avoid playing God, Med Mal Infect. juill, vol.46, issue.5, pp.242-68, 2016.

, Soc Nephrologie :: calculateur clairance créatinine corrigée

M. Disponible-sur-;-quirins and N. Weiss, Encéphalopathies médicamenteuses, une approche pratique pour le clinicien, Prat Neurol-FMC. 1 févr, vol.5, pp.39-48, 2014.

F. Pea, P. Viale, P. Cojutti, and M. Furlanut, Dosing Nomograms for Attaining Optimum Concentrations of Méropenème by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach

, Antimicrob Agents Chemother. déc, vol.56, issue.12, pp.6343-6351, 2012.

P. Cojutti, N. Maximova, F. Pea, J. Goncalves-pereira, N. E. Silva et al., Pharmacokinetics and Pharmacodynamics of Continuous-Infusion Méropenème in Pediatric Hematopoietic Stem Cell Transplant Patients, Antimicrob Agents Chemother. 9 janv, vol.59, issue.9, p.21, 2014.

T. M. Chapuis, E. Giannoni, P. A. Majcherczyk, R. Chioléro, M. Schaller et al., Prospective monitoring of cefepime in intensive care unit adult patients, Crit Care Lond Engl, vol.14, issue.2, p.51, 2010.

, European Medicines Agency

J. Lipman, C. D. Gomersall, T. Gin, G. M. Joynt, and R. J. Young, Continuous infusion ceftazidime in intensive care: a randomized controlled trial, J Antimicrob Chemother. févr, vol.43, issue.2, pp.309-320, 1999.

G. Aubert, A. Carricajo, M. Coudrot, S. Guyomarc'h, C. Auboyer et al., Prospective determination of serum ceftazidime concentrations in intensive care units, Ther Drug Monit. août, vol.32, issue.4, pp.517-526, 2010.

J. M. Conil, B. Georges, M. Lavit, T. Seguin, I. Tack et al., Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance, Int J Clin Pharmacol Ther, vol.45, issue.10, pp.529-567, 2007.

A. Novelli, C. Adembri, P. Livi, S. Fallani, T. Mazzei et al., Pharmacokinetic evaluation of méropenème and imipenem in critically ill patients with sepsis, Clin Pharmacokinet, vol.44, issue.5, pp.539-588, 2005.

R. Kitzes-cohen, D. Farin, and G. Piva, Myttenaere-Bursztein SAD. Pharmacokinetics and pharmacodynamics of méropenème in critically ill patients, Int J Antimicrob Agents. 1 févr, vol.19, issue.2, pp.105-115, 2002.

F. Pea, D. Siega, P. Cojutti, P. Sartor, A. Crapis et al., Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion méropenème improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?, Int J Antimicrob Agents. févr, vol.49, issue.2, pp.255-263, 2017.

J. J. De-waele, S. Carrette, M. Carlier, V. Stove, J. Boelens et al., Therapeutic drug monitoring-based dose optimisation of piperacillin and méropenème: a randomised controlled trial, Intensive Care Med. mars, vol.40, issue.3, pp.380-387, 2014.

F. Thalhammer, F. Traunmüller, E. Menyawi, I. Frass, M. Hollenstein et al.,

L. Lorente, S. Huidobro, M. Martín, and M. Mora, Méropenème administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia, Crit Care, vol.9, issue.1, p.38, 2005.

S. Jaruratanasirikul and S. Sriwiriyajan, Stability of méropenème in normal saline solution after storage at room temperature, Southeast Asian J Trop Med Public Health. sept, vol.34, issue.3, pp.627-636, 2003.

G. Marie, F. Maganti-rama, and K. , Neurotoxic effects associated with antibiotic use: management considerations, Br J Clin Pharmacol. 18 avr, vol.72, issue.3, pp.381-93, 2011.

M. Campise, Neurological complication during imipenem/cilastatin therapy in uraemic patients, Nephrol Dial Transplant. 1 juill, vol.13, issue.7, pp.1895-1901, 1998.

M. Hites, F. S. Taccone, F. Wolff, E. Maillart, M. Beumier et al., Broad-spectrum ?-lactams in obese non-critically ill patients, Nutr Diabetes. juin, vol.4, issue.6, p.119, 2014.

S. E. Schliamser, O. Cars, and S. R. Norrby, Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis, J Antimicrob Chemother. avr, vol.27, issue.4, pp.405-430, 1991.

G. Naeije, S. Lorent, J. Vincent, and B. Legros, Continuous epileptiform discharges in patients treated with cefepime or méropenème, Arch Neurol, vol.68, issue.10, pp.1303-1310, 2011.

A. Tanaka, K. Takechi, S. Watanabe, M. Tanaka, K. Suemaru et al., Comparison of the prevalence of convulsions associated with the use of cefepime and méropenème, Int J Clin Pharm, vol.35, issue.5, pp.683-690, 2013.

F. Pea, P. Viale, and M. Furlanut, Antimicrobial Therapy in Critically Ill Patients, Clin Pharmacokinet, vol.44, issue.10, pp.1009-1043, 2005.

P. De-paepe, F. M. Belpaire, and W. A. Buylaert, Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock, Clin Pharmacokinet, vol.41, issue.14, pp.1135-51, 2002.

B. M. Power, A. M. Forbes, P. V. Van-heerden, and K. F. Ilett, Pharmacokinetics of drugs used in critically ill adults, Clin Pharmacokinet. janv, vol.34, issue.1, pp.25-56, 1998.

R. Mehrotra, D. Gaudio, R. Palazzo, and M. , Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness, Intensive Care Med. déc, vol.30, issue.12, pp.2145-56, 2004.

A. Bodenham, M. P. Shelly, and G. R. Park, The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients, Clin Pharmacokinet. juin, vol.14, issue.6, pp.347-73, 1988.

G. M. Joynt, J. Lipman, C. D. Gomersall, R. J. Young, E. L. Wong et al., The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients, J Antimicrob Chemother. avr, vol.47, issue.4, pp.421-430, 2001.

, Age

, Sexe masculin-n (%) 93 (65%) 51 (63%), p.33

D. De,

, Durée de séjour en réanimation (jours), p.34

. Ecmo/ecls-À-j4-n,

. Hématocrite, , p.28

A. , , vol.28, p.1

. Créatininémie, , pp.44-77

, # signale une différence significative en analyse univariée par rapport au sous-groupe sous-dosé / sur-dosé

, * signale une différence significative en analyse univariée par rapport au sous-groupe normodosé

, # signale une différence significative en analyse univariée par rapport au sous-groupe sous-dosé / sur-dosé

, * signale une différence significative en analyse univariée par rapport au sous-groupe normodosé

, Appendice 1 : Protocole d'administration et d'adaptation de posologies des bêtalactamines